If you purchased brand or generic Intuniv directly from a manufacturer between October 19, 2012, and June 1, 2015, you may be eligible to claim a portion of a $58,000,000 class action settlement.
Shire has agreed to pay $58,000,000 to settle a class action lawsuit for alleged antitrust violations related to delaying the market entry of generic versions of Intuniv.
Who Can Claim an Award?
To be eligible for the settlement, you must be a person or entity in the United States or its territories that purchased brand or generic Intuniv directly from Shire or Actavis between October 19, 2012, and June 1, 2015. This includes any predecessor or successor of Shire or Actavis.
What Awards Can Class Members Claim?
The settlement provides for a $58,000,000 fund to be distributed among class members. After deducting court-approved attorneys' fees, litigation expenses, administration costs, and incentive awards for the class representatives, the remaining amount will be divided among class members who submit valid claim forms, which will be mailed after the court approves the settlement.
$58,000,000 Settlement Fund
The total settlement amount is $58,000,000. This amount will be used to cover:
- Attorneys' fees: up to one-third of the settlement fund
- Litigation expenses
- Administration costs
- Incentive awards for class representatives: $50,000 each
- Net Settlement Fund: the remaining amount to be distributed to class members
Important Dates
- Fairness Hearing: November 6, 2024
- Deadline to File a Claim: TBD
Why is There a Class Action Settlement?
The lawsuit alleges that Shire and Actavis violated antitrust laws by delaying the market entry of generic versions of Intuniv, causing purchasers to pay higher prices for the drug. By settling, both parties avoid the risks and uncertainties of a trial.
What Happens Next?
The court will hold a Fairness Hearing on November 6, 2024, to decide whether to grant final approval of the settlement. If approved, the settlement fund will be distributed to class members who submitted valid claims.
Comments